Genera’s low false negatives
Wednesday, 15 October, 2008
Pilot clinical trials of Genera Biosystems' [ASX: GBI] new PapType HPV detection test have shown that the test gives improved detection rates of cervical cancer than the market leader test.
Currently Qiagen's Hybrid Capture 2 test (HC2) is the only FDA-approved test for cervical cancer screening.
But in Genera's latest trials, PapType outperformed the HC2 test, returning a false negative rate of seven per cent, compared to a 27 per cent false negative rate with HC2.
Genera believes the results are very encouraging, although they are not yet conclusive.
For example, all the women in the study already had an abnormal pap smear. According to Genera, trials from the general population will need to be conducted before the superiority of PapType can be confirmed.
Clogged 'drains' in the brain an early sign of Alzheimer’s
'Drains' in the brain, responsible for clearing toxic waste in the organ, tend to get...
World's oldest known RNA extracted from woolly mammoth
The RNA sequences are understood to be the oldest ever recovered, coming from mammoth tissue...
The voice of reason: natural language interfaces to transform lab informatics
In everyday life, voice interaction with technology can save time and reduce friction. The same...
